Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy play

44:49
 
Share
 

Manage episode 510263825 series 3361449
Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Raising money in the gene therapy space can be tough right now but, for the right company and with the right team, there is still cash to be found. But how do you connect with investors, how do you get your science in front of the right people, and how do you move from ‘I’m interested’ to ‘I’m signing on the dotted line’?

This week I talk with Gerard Caelles, Chief Business Office of Splice Bio, a company that just closed a $135 million series B fundraising round. I quiz him on the practical steps that biotechs need to take to move from a series A to a series B, the key members of the team that pulled the deal together, how to keep existing investors engaged while bringing new money on-board, and how it feels when it is all done.

01:14 Meet Gerard Caelles

04:34 The Splice Bio platform

12:34 Raising $135 million in uncertain times

15:31 Laying the groundwork for a series B

18:15 Building a fundraising team

20:45 Identifying and approaching new investors

22:38 Fundraising challenges in 2025

26:37 Refining the strategy and pitch

29:00 Choosing lead investors

31:59 Keeping existing investors on board

34:12 A look behind the scenes

37:52 What’s next for Splice Bio

42:10 Learn more about Splice Bio

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

  continue reading

Chapters

1. Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy play (00:00:00)

2. Meet Gerard Caelles (00:01:14)

3. The Splice Bio platform (00:04:34)

4. Raising $135 million in uncertain times (00:12:34)

5. Laying the groundwork for a series B (00:15:31)

6. Building a fundraising team (00:18:15)

7. Identifying and approaching new investors (00:20:45)

8. Fundraising challenges in 2025 (00:22:38)

9. Refining the strategy and pitch (00:26:37)

10. Choosing lead investors (00:29:00)

11. Keeping existing investors on board (00:31:59)

12. A look behind the scenes (00:34:12)

13. What’s next for Splice Bio (00:37:52)

14. Learn more about Splice Bio (00:42:10)

168 episodes

Artwork
iconShare
 
Manage episode 510263825 series 3361449
Content provided by Labiotech. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Labiotech or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Raising money in the gene therapy space can be tough right now but, for the right company and with the right team, there is still cash to be found. But how do you connect with investors, how do you get your science in front of the right people, and how do you move from ‘I’m interested’ to ‘I’m signing on the dotted line’?

This week I talk with Gerard Caelles, Chief Business Office of Splice Bio, a company that just closed a $135 million series B fundraising round. I quiz him on the practical steps that biotechs need to take to move from a series A to a series B, the key members of the team that pulled the deal together, how to keep existing investors engaged while bringing new money on-board, and how it feels when it is all done.

01:14 Meet Gerard Caelles

04:34 The Splice Bio platform

12:34 Raising $135 million in uncertain times

15:31 Laying the groundwork for a series B

18:15 Building a fundraising team

20:45 Identifying and approaching new investors

22:38 Fundraising challenges in 2025

26:37 Refining the strategy and pitch

29:00 Choosing lead investors

31:59 Keeping existing investors on board

34:12 A look behind the scenes

37:52 What’s next for Splice Bio

42:10 Learn more about Splice Bio

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

  continue reading

Chapters

1. Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy play (00:00:00)

2. Meet Gerard Caelles (00:01:14)

3. The Splice Bio platform (00:04:34)

4. Raising $135 million in uncertain times (00:12:34)

5. Laying the groundwork for a series B (00:15:31)

6. Building a fundraising team (00:18:15)

7. Identifying and approaching new investors (00:20:45)

8. Fundraising challenges in 2025 (00:22:38)

9. Refining the strategy and pitch (00:26:37)

10. Choosing lead investors (00:29:00)

11. Keeping existing investors on board (00:31:59)

12. A look behind the scenes (00:34:12)

13. What’s next for Splice Bio (00:37:52)

14. Learn more about Splice Bio (00:42:10)

168 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play